Mostrar el registro sencillo del ítem
Real-world safety and efficacy data of immunotherapy in patients with cancer and autoimmune disease: the experience of the Hellenic Cooperative Oncology Group
dc.creator | Fountzilas E., Lampaki S., Koliou G.-A., Koumarianou A., Levva S., Vagionas A., Christopoulou A., Laloysis A., Psyrri A., Binas I., Mountzios G., Kentepozidis N., Kotsakis A., Saloustros E., Boutis A., Nikolaidi A., Fountzilas G., Georgoulias V., Chrysanthidis M., Kotteas E., Vo H., Tsiatas M., Res E., Linardou H., Daoussis D., Bompolaki I., Andreadou A., Papaxoinis G., Spyratos D., Gogas H., Syrigos K.N., Bafaloukos D. | en |
dc.date.accessioned | 2023-01-31T07:38:43Z | |
dc.date.available | 2023-01-31T07:38:43Z | |
dc.date.issued | 2022 | |
dc.identifier | 10.1007/s00262-021-02985-6 | |
dc.identifier.issn | 03407004 | |
dc.identifier.uri | http://hdl.handle.net/11615/71749 | |
dc.description.abstract | Background: Data on the safety and efficacy of immune checkpoint inhibitors (ICI) in patients with concurrent autoimmune diseases (AID) are limited. Methods: We performed a retrospective multicenter review of medical records of patients with cancer and underlying AID who received ICI. The primary endpoint was progression-free survival (PFS). Results: Among 123 patients with pre-existing AID who received ICI, the majority had been diagnosed with non-small cell lung cancer (NSCLC, 68.3%) and melanoma (14.6%). Most patients had a rheumatologic (43.9%), or an endocrine disorder (21.1%). Overall, 74 (60.2%) patients experienced an immune-related adverse event (irAE) after ICI initiation, AID flare (25.2%), or new irAE (35%). Frequent irAEs included thyroiditis, dermatitis and colitis. ICI was permanently discontinued due to unacceptable (8.1%) or fatal (0.8%) toxicity. In patients with NSCLC, corticosteroid treatment at the initiation of immunotherapy was associated with poor PFS (HR = 2.78, 95% CI 1.40–5.50, p = 0.003). The occurrence of irAE was associated with increased PFS (HR = 0.48, 95% CI 0.25–0.92, p = 0.026). Both parameters maintained their independent prognostic significance. Conclusions: ICI in patients with cancer and pre-existing AID is associated with manageable toxicity that infrequently requires treatment discontinuation. However, since severe AID flare might occur, expected ICI efficacy and toxicity must be balanced. Clinical trial identifier: NCT04805099. © 2021, The Author(s). | en |
dc.language.iso | en | en |
dc.source | Cancer Immunology, Immunotherapy | en |
dc.source.uri | https://www.scopus.com/inward/record.uri?eid=2-s2.0-85108625467&doi=10.1007%2fs00262-021-02985-6&partnerID=40&md5=da07eeffdda8457f4d8829acb6444c82 | |
dc.subject | atezolizumab | en |
dc.subject | avelumab | en |
dc.subject | azathioprine | en |
dc.subject | corticosteroid | en |
dc.subject | cyclosporine | en |
dc.subject | durvalumab | en |
dc.subject | etanercept | en |
dc.subject | hydroxychloroquine | en |
dc.subject | immune checkpoint inhibitor | en |
dc.subject | ipilimumab | en |
dc.subject | leflunomide | en |
dc.subject | methotrexate | en |
dc.subject | nivolumab | en |
dc.subject | pembrolizumab | en |
dc.subject | phosphodiesterase IV inhibitor | en |
dc.subject | programmed death 1 ligand 1 | en |
dc.subject | salazosulfapyridine | en |
dc.subject | ustekinumab | en |
dc.subject | adult | en |
dc.subject | aged | en |
dc.subject | Article | en |
dc.subject | autoimmune disease | en |
dc.subject | cancer immunotherapy | en |
dc.subject | cancer prognosis | en |
dc.subject | clinical trial (topic) | en |
dc.subject | cohort analysis | en |
dc.subject | colitis | en |
dc.subject | corticosteroid therapy | en |
dc.subject | dermatitis | en |
dc.subject | diagnostic value | en |
dc.subject | drug efficacy | en |
dc.subject | drug safety | en |
dc.subject | drug withdrawal | en |
dc.subject | female | en |
dc.subject | follow up | en |
dc.subject | human | en |
dc.subject | major clinical study | en |
dc.subject | male | en |
dc.subject | malignant neoplasm | en |
dc.subject | melanoma | en |
dc.subject | non small cell lung cancer | en |
dc.subject | overall survival | en |
dc.subject | progression free survival | en |
dc.subject | protein expression | en |
dc.subject | psoriasis | en |
dc.subject | retrospective study | en |
dc.subject | thyroiditis | en |
dc.subject | toxicity | en |
dc.subject | treatment response | en |
dc.subject | autoimmune disease | en |
dc.subject | immunology | en |
dc.subject | immunotherapy | en |
dc.subject | middle aged | en |
dc.subject | mortality | en |
dc.subject | neoplasm | en |
dc.subject | pathology | en |
dc.subject | prognosis | en |
dc.subject | survival rate | en |
dc.subject | very elderly | en |
dc.subject | Adult | en |
dc.subject | Aged | en |
dc.subject | Aged, 80 and over | en |
dc.subject | Autoimmune Diseases | en |
dc.subject | Female | en |
dc.subject | Follow-Up Studies | en |
dc.subject | Humans | en |
dc.subject | Immune Checkpoint Inhibitors | en |
dc.subject | Immunotherapy | en |
dc.subject | Male | en |
dc.subject | Middle Aged | en |
dc.subject | Neoplasms | en |
dc.subject | Prognosis | en |
dc.subject | Retrospective Studies | en |
dc.subject | Survival Rate | en |
dc.subject | Springer Science and Business Media Deutschland GmbH | en |
dc.title | Real-world safety and efficacy data of immunotherapy in patients with cancer and autoimmune disease: the experience of the Hellenic Cooperative Oncology Group | en |
dc.type | journalArticle | en |
Ficheros en el ítem
Ficheros | Tamaño | Formato | Ver |
---|---|---|---|
No hay ficheros asociados a este ítem. |